Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Seventy-nine patients with panic disorder were randomized to an 8-week double-blind treatment with alprazolam, imipramine, or placebo. Patients kept daily records of panic attacks, activity, anxiety, sleep, and medication use. Weekly measures of anxiety, depression, somatic symptoms, fears, avoidance, disability, and improvement were obtained. All patients underwent a symptom-limited exercise treadmill and other cardiovascular measures. By physician and patient global assessment, patients receiving alprazolam or imipramine were significantly better than patients on placebo. The alprazolam effects were apparent by week 1; the imipramine effects by week 4. All groups showed significant reductions in anxiety, depression, somatic measures, and panic attack frequency. At 8 weeks, patients in the alprazolam group reported significantly less fear than patients in the other two groups. Subjects in the imipramine group showed a significant increase in heart rate and blood pressure.

Type

Journal article

Journal

J Clin Psychopharmacol

Publication Date

04/1990

Volume

10

Pages

112 - 118

Keywords

Adult, Agoraphobia, Alprazolam, Analysis of Variance, Anxiety, Anxiety Disorders, Depression, Disability Evaluation, Double-Blind Method, Fear, Female, Hemodynamics, Humans, Imipramine, Male, Panic, Psychiatric Status Rating Scales, Randomized Controlled Trials as Topic